Glioblastoma in the Elderly: The Impact of Advanced Age on Treatment and Survival

 

 Permissions and Reprints

Abstract

Objective To evaluate the effects of combined treatments on the outcome and survival of elderly (≥ 65 years) patients with glioblastoma as compared with younger ones.

Material and Methods Fifty consecutive elderly (≥ 65 years) patients (group A) who underwent complete or subtotal (> 80%) resection of brain glioblastoma followed by irradiation and chemotherapy with temozolomide between 2004 and 2009 were retrospectively reviewed and compared with 50 glioblastoma patients aged < 65 years, treated in the same period (group B). Patient sex, tumor location, size and side, combined treatments, reoperation, progression-free survival, and overall survival were compared in the two groups by using the Kaplan-Meyer method.

Results There were no significant differences between the two groups for tumor location, size and side, and K_i-67 Li. Forty-four of 50 group B patients were treated by the Stupp protocol, whereas all group A patients underwent irradiation and adjuvant temozolomide. Second-line chemotherapy was administrated in 32% of group A and 76% of group B cases, and reoperation was performed in 16% and 36%, respectively. The median survival of the overall series of 100 patients was 15.6 months. Group A patients (≥ 65 years) had a median survival of 14.5 months, significantly lower than group B cases (17 months) (p = 0.02).

Conclusion Elderly patients with glioblastoma may benefit from combined treatments, including surgery, radiotherapy, and chemotherapy. Although younger patients do survive longer than older ones, the difference of survival is less significant if several criteria of selection to surgery, such as good Karnofsky performance status (KPS), largely resectable tumor, and no significant comorbidity, are respected.

• References

• 1 Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 2002; 4 (4) 278-299
  PubMedGoogle Scholar
• 2 Greig NH, Ries LG, Yancik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990; 82 (20) 1621-1624
  CrossrefPubMedGoogle Scholar
• 3 Stark AM, Hedderich J, Held-Feindt J, Mehdorn HM. Glioblastoma—the consequences of advanced patient age on treatment and survival. Neurosurg Rev 2007; 30 (1) 56-61 , discussion 61–62
  CrossrefPubMedGoogle Scholar
• 4 Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol 2011; 103 (3) 611-618
  CrossrefPubMedGoogle Scholar
• 5 Stark AM, Nabavi A, Mehdorn HM, Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005; 63 (2) 162-169 , discussion 169
  CrossrefPubMedGoogle Scholar
• 6 Stupp R, Mason WP, van den Bent MJ , et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
  CrossrefPubMedGoogle Scholar
• 7 Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998; 88 (1) 1-10
  CrossrefPubMedGoogle Scholar
• 8 Scott JN, Rewcastle NB, Brasher PM , et al. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 1998; 25 (3) 197-201
  PubMedGoogle Scholar
• 9 Lacroix M, Abi-Said D, Fourney DR , et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (2) 190-198
  Google Scholar
• 10 Stummer W, Reulen HJ, Meinel T , et al; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62 (3) 564-576 , discussion 564–576
  CrossrefPubMedGoogle Scholar
• 11 Casartelli G, Dorcaratto A, Ravetti JL , et al. Survival of high grade glioma patients depends on their age at diagnosis. Cancer Biol Ther 2009; 8 (18) 1719-1721
  CrossrefPubMedGoogle Scholar
• 12 Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994; 34 (1) 62-66 , discussion 66–67
  CrossrefPubMedGoogle Scholar
• 13 Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 1998; 42 (5) 981-987
  CrossrefPubMedGoogle Scholar
• 14 Whittle IR, Basu N, Grant R, Walker M, Gregor A. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg 2002; 16 (4) 343-347
  CrossrefPubMedGoogle Scholar
• 15 Brandes AA, Vastola F, Basso U , et al. A prospective study on glioblastoma in the elderly. Cancer 2003; 97 (3) 657-662
  CrossrefPubMedGoogle Scholar
• 16 Iwamoto FM, Cooper AR, Reiner AS, Nayak L, Abrey LE. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer 2009; 115 (16) 3758-3766
  CrossrefPubMedGoogle Scholar
• 17 Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006; 12 (3) 143-147
  CrossrefPubMedGoogle Scholar
• 18 Uehara K, Sasayama T, Miyawaki D , et al. Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. Radiat Oncol 2012; 7: 104
  CrossrefPubMedGoogle Scholar
• 19 Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003; 145 (1) 5-10
  CrossrefPubMedGoogle Scholar
• 20 Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999; 52 (4) 371-379
  CrossrefPubMedGoogle Scholar
• 21 Pichlmeier U, Bink A, Schackert G, Stummer W ; ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro-oncol 2008; 10 (6) 1025-1034
  PubMedGoogle Scholar
• 22 Pierga JY, Hoang-Xuan K, Feuvret L , et al. Treatment of malignant gliomas in the elderly. J Neurooncol 1999; 43 (2) 187-193
  CrossrefPubMedGoogle Scholar
• 23 Brandes AA, Franceschi E, Tosoni A , et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009; 115 (15) 3512-3518
  CrossrefPubMedGoogle Scholar
• 24 Combs SE, Wagner J, Bischof M , et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008; 70 (4) 987-992
  CrossrefPubMedGoogle Scholar
• 25 Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009; 94 (1) 97-101
  CrossrefPubMedGoogle Scholar
• 26 Minniti G, Amelio D, Amichetti M , et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97 (3) 377-381
  CrossrefPubMedGoogle Scholar
• 27 Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009; 73 (18) 1509-1510
  CrossrefPubMedGoogle Scholar
• 28 Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P. Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci 2010; 37 (5) 625-630
  CrossrefPubMedGoogle Scholar
• 29 Costa BM, Caeiro C, Guimarães I , et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 2010; 23 (6) 1655-1662
  PubMedGoogle Scholar
• 30 Abhinav K, Aquilina K, Gbejuade H, La M, Hopkins K, Iyer V. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival. Clin Neurol Neurosurg 2013; 115 (8) 1375-1378
  CrossrefPubMedGoogle Scholar
• 31 Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate?. Br J Neurosurg 2008; 22 (3) 452-455
  CrossrefPubMedGoogle Scholar
• 32 Helseth R, Helseth E, Johannesen TB , et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122 (3) 159-167
  CrossrefPubMedGoogle Scholar
• 33 Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 2008; 69 (5) 506-509 , discussion 509
  CrossrefPubMedGoogle Scholar
• 34 Simmons ML, Lamborn KR, Takahashi M , et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61 (3) 1122-1128
  PubMedGoogle Scholar
• 35 Batchelor TT, Betensky RA, Esposito JM , et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10 (1 Pt 1) 228-233
  CrossrefPubMedGoogle Scholar